OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up
I'm PortAI, I can summarize articles.
OS Therapies, Inc. (OSTX) has announced an asset purchase agreement to acquire immuno-oncology programs and related IP from Ayala Pharmaceuticals (ADXS) for $0.5 million in cash and $7.5 million in common shares. This includes a Phase 2 lung cancer and Phase 1 prostate cancer program. The deal is expected to close within 60 days. OST Therapies plans to request Biologics Licensing Authorization for its lead asset, OST-HER2, in 2025. OSTX shares rose 9.61% to $2.85 on the NYSE.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments